Laurus Labs Limited (BOM:540222)

Market Cap	542.99B
Revenue (ttm)	63.58B
Net Income (ttm)	6.84B
Shares Out	n/a
EPS (ttm)	12.67
PE Ratio	79.39
Forward PE	65.95
Dividend	1.60 (0.15%)
Ex-Dividend Date	Oct 31, 2025

Volume	72,879
Average Volume	69,283
Open	1,001.55
Previous Close	988.75
Day's Range	986.50 - 1,022.20
52-Week Range	504.30 - 1,140.90
Beta	n/a
RSI	39.38
Earnings Date	Jan 23, 2026

About Laurus Labs

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition,...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2005
• Employees: 6,167
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 540222

Financial Performance

In 2024, Laurus Labs's revenue was 55.54 billion, an increase of 10.18% compared to the previous year's 50.41 billion. Earnings were 3.58 billion, an increase of 123.18%.